Literature DB >> 17440811

Systemic neurochemical alterations in schizophrenic brain: glutamate metabolism in focus.

Gulnur Sh Burbaeva1, Irina S Boksha, Elena B Tereshkina, Olga K Savushkina, Lubov' I Starodubtseva, Marina S Turishcheva, Elizabeta Mukaetova-Ladinska.   

Abstract

We have used a systemic approach to establish a relationship between enzyme measures of glial glutamate and energy metabolism (glutamine synthetase and glutamine synthetase-like protein, glutamate dehydrogenase isoenzymes, brain isoform creatine phosphokinase) and two major glial proteins (glial fibrillary acidic protein and myelin basic protein) in autopsied brain samples taken from patients with schizophrenia (SCH) and mentally healthy subjects (23 and 22 cases, respectively). These biochemical parameters were measured in tissue extracts in three brain areas (prefrontal cortex, caudate nucleus, and cerebellum). Significant differences in the level of at least one of the glutamate metabolizing enzymes were observed between two studied groups in all studied brain areas. Different patterns of correlative links between the biochemical parameters were found in healthy and schizophrenic brains. These findings give a new perspective to our understanding of the impaired regulation of enzyme levels in the brain in SCH.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17440811     DOI: 10.1007/s11064-007-9328-7

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  49 in total

1.  Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia.

Authors:  I Maurer; S Zierz; H Möller
Journal:  Schizophr Res       Date:  2001-03-01       Impact factor: 4.939

Review 2.  Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions.

Authors:  G E Alexander; M D Crutcher; M R DeLong
Journal:  Prog Brain Res       Date:  1990       Impact factor: 2.453

3.  Mitochondrial activity in the mapping of functional brain changes in schizophrenia.

Authors:  J A Prince; L Oreland
Journal:  Restor Neurol Neurosci       Date:  1998-06       Impact factor: 2.406

4.  Functional dysconnectivity in schizophrenia associated with attentional modulation of motor function.

Authors:  Garry D Honey; Edith Pomarol-Clotet; Philip R Corlett; Rebekah A E Honey; Peter J McKenna; Edward T Bullmore; Paul C Fletcher
Journal:  Brain       Date:  2005-09-23       Impact factor: 13.501

5.  Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene.

Authors:  Mirjana Tosic; Jurg Ott; Sandra Barral; Pierre Bovet; Patricia Deppen; Fulvia Gheorghita; Marie-Louise Matthey; Josef Parnas; Martin Preisig; Michael Saraga; Alessandra Solida; Sally Timm; August G Wang; Thomas Werge; Michel Cuénod; Kim Quang Do
Journal:  Am J Hum Genet       Date:  2006-07-31       Impact factor: 11.025

Review 6.  NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders.

Authors:  J H Krystal; D C D'Souza; I L Petrakis; A Belger; R M Berman; D S Charney; W Abi-Saab; S Madonick
Journal:  Harv Rev Psychiatry       Date:  1999 Sep-Oct       Impact factor: 3.732

7.  Glial fibrillary acidic protein and glutamine synthetase in subregions of prefrontal cortex in schizophrenia and mood disorder.

Authors:  Carla T Toro; Jaime E C Hallak; Jason S Dunham; John F W Deakin
Journal:  Neurosci Lett       Date:  2006-07-13       Impact factor: 3.046

8.  Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients.

Authors:  Martin R Gluck; Rohan G Thomas; Kenneth L Davis; Vahram Haroutunian
Journal:  Am J Psychiatry       Date:  2002-07       Impact factor: 18.112

9.  Frontostriatal disorder of cerebral metabolism in never-medicated schizophrenics.

Authors:  M S Buchsbaum; R J Haier; S G Potkin; K Nuechterlein; H S Bracha; M Katz; J Lohr; J Wu; S Lottenberg; P A Jerabek
Journal:  Arch Gen Psychiatry       Date:  1992-12

10.  Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium.

Authors:  Natalya A Uranova; Victor M Vostrikov; Diana D Orlovskaya; Valentina I Rachmanova
Journal:  Schizophr Res       Date:  2004-04-01       Impact factor: 4.939

View more
  6 in total

Review 1.  The cerebellum, cerebellar disorders, and cerebellar research--two centuries of discoveries.

Authors:  Mario Manto
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

Review 2.  Behavioral sequelae of astrocyte dysfunction: focus on animal models of schizophrenia.

Authors:  Meng Xia; Sofya Abazyan; Yan Jouroukhin; Mikhail Pletnikov
Journal:  Schizophr Res       Date:  2014-11-20       Impact factor: 4.939

3.  Glutamate Dehydrogenase-Deficient Mice Display Schizophrenia-Like Behavioral Abnormalities and CA1-Specific Hippocampal Dysfunction.

Authors:  Sharon S Lander; Usman Khan; Nicole Lewandowski; Darpan Chakraborty; Frank A Provenzano; Susana Mingote; Sergiy Chornyy; Francesca Frigerio; Pierre Maechler; Hanoch Kaphzan; Scott A Small; Stephen Rayport; Inna Gaisler-Salomon
Journal:  Schizophr Bull       Date:  2019-01-01       Impact factor: 9.306

Review 4.  Multiple Forms of Glutamate Dehydrogenase in Animals: Structural Determinants and Physiological Implications.

Authors:  Victoria Bunik; Artem Artiukhov; Vasily Aleshin; Garik Mkrtchyan
Journal:  Biology (Basel)       Date:  2016-12-14

Review 5.  Magnetic Resonance Spectroscopy in Schizophrenia: Evidence for Glutamatergic Dysfunction and Impaired Energy Metabolism.

Authors:  João M N Duarte; Lijing Xin
Journal:  Neurochem Res       Date:  2018-04-03       Impact factor: 3.996

6.  Igg-Dependent Hydrolysis of Myelin Basic Protein of Patients with Different Courses of Schizophrenia.

Authors:  Daria A Parshukova; Liudmila P Smirnova; Elena G Kornetova; Arkadiy V Semke; Valentina N Buneva; Svetlana A Ivanova
Journal:  J Immunol Res       Date:  2020-08-10       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.